Q-omics provides the consensus-scored HFM1 profile across patient tissues and cancer cell-line models. HFM1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, HFM1 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, HFM1 RNA expression shows 17,831 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KICH, and UVM as cancer lineages where HFM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HFM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HFM1 survival associations across molecular data types. HFM1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HFM1 RNA expression–survival associations across cancer types. High HFM1 expression shows unfavorable associations in KICH, UCEC, LIHC and COAD, but favorable associations in UCS and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for HFM1 RNA expression.
This table summarizes HFM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HFM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HFM1 shows lower tumor expression in KICH, THCA, KIRC, HNSC, BRCA and LUSC. The KICH box plot shows higher HFM1 RNA expression in normal versus tumor tissue (log2 FC = −0.779, t-test p < 0.001).
This table shows molecular features associated with HFM1 in patient tissues and cancer cell lines. In patient samples, HFM1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HFM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
